$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2023 Q1 Form 10-K Financial Statement

#000141057823000426 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.227M $2.464M $10.87M
YoY Change -22.11% -2.8% 16.79%
% of Gross Profit
Research & Development $2.924M $2.451M $13.96M
YoY Change 11.77% -33.34% -8.4%
% of Gross Profit
Depreciation & Amortization $67.00K $70.00K $285.0K
YoY Change -9.46% 0.0% 9.62%
% of Gross Profit
Operating Expenses $2.924M $4.915M $13.96M
YoY Change 11.77% -20.88% -8.4%
Operating Profit -$5.151M -$24.82M
YoY Change -5.92% 1.15%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $92.00K -$103.0K $545.0K
YoY Change -20.0% -568.18% 564.63%
Pretax Income -$5.059M -$5.018M -$24.28M
YoY Change -5.62% -18.93% -0.74%
Income Tax
% Of Pretax Income
Net Earnings -$5.059M -$5.018M -$24.28M
YoY Change -5.62% -18.93% -0.74%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.66
Diluted Earnings Per Share -$0.14 -$0.14 -$0.66
COMMON SHARES
Basic Shares Outstanding 36.68M 36.54M 36.51M
Diluted Shares Outstanding 36.74M 36.51M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.227M $2.983M $2.983M
YoY Change -87.89% -86.5% -86.5%
Cash & Equivalents $2.021M $772.0K $772.0K
Short-Term Investments $206.0K $2.211M $2.211M
Other Short-Term Assets $658.0K $32.00K $32.00K
YoY Change -17.96% -97.09% -97.09%
Inventory
Prepaid Expenses
Receivables $44.00K $91.00K $91.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.929M $3.106M $3.106M
YoY Change -84.79% -86.66% -86.66%
LONG-TERM ASSETS
Property, Plant & Equipment $866.0K $933.0K $5.322M
YoY Change -22.95% -21.53% -10.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.943M $5.345M $23.00K
YoY Change -24.31% -10.87% -14.81%
Total Long-Term Assets $4.943M $5.345M $5.345M
YoY Change -24.31% -10.87% -10.87%
TOTAL ASSETS
Total Short-Term Assets $2.929M $3.106M $3.106M
Total Long-Term Assets $4.943M $5.345M $5.345M
Total Assets $7.872M $8.451M $8.451M
YoY Change -69.48% -71.13% -71.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.802M $6.224M $6.224M
YoY Change 70.72% 68.22% 68.22%
Accrued Expenses $171.0K $84.00K $1.511M
YoY Change 140.85% 1.2% -2.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.42M $8.800M $8.800M
YoY Change 41.37% 39.31% 39.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.290M $2.666M $2.666M
YoY Change -41.76% -26.31% -26.31%
Total Long-Term Liabilities $2.290M $2.666M $2.666M
YoY Change -41.76% -26.31% -26.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.42M $8.800M $8.800M
Total Long-Term Liabilities $2.290M $2.666M $2.666M
Total Liabilities $12.71M $11.47M $11.47M
YoY Change 12.46% 15.41% 15.41%
SHAREHOLDERS EQUITY
Retained Earnings -$202.9M -$198.0M
YoY Change 13.34% 14.09%
Common Stock $198.2M $194.9M
YoY Change 2.4% 0.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.840M -$3.015M -$3.015M
YoY Change
Total Liabilities & Shareholders Equity $7.872M $8.451M $8.451M
YoY Change -69.48% -71.13% -71.13%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$5.059M -$5.018M -$24.28M
YoY Change -5.62% -18.93% -0.74%
Depreciation, Depletion And Amortization $67.00K $70.00K $285.0K
YoY Change -9.46% 0.0% 9.62%
Cash From Operating Activities -$3.986M -$4.648M -$19.32M
YoY Change 8.08% -15.61% -26.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $29.00K
YoY Change -100.0% -100.0% -91.21%
Acquisitions
YoY Change
Other Investing Activities $2.005M $1.038M $1.027M
YoY Change -25162.5% -182.25% 57.27%
Cash From Investing Activities $2.005M $1.038M $998.0K
YoY Change -11894.12% -180.03% 208.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $151.0K
YoY Change 0.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.230M 238.0K 238.0K
YoY Change -800.0% -96.58%
NET CHANGE
Cash From Operating Activities -3.986M -4.648M -19.32M
Cash From Investing Activities 2.005M 1.038M 998.0K
Cash From Financing Activities 3.230M 238.0K 238.0K
Net Change In Cash 1.249M -3.372M -18.08M
YoY Change -133.71% -50.69% -4.69%
FREE CASH FLOW
Cash From Operating Activities -$3.986M -$4.648M -$19.32M
Capital Expenditures $0.00 $0.00 $29.00K
Free Cash Flow -$3.986M -$4.648M -$19.35M
YoY Change 7.82% -15.07% -27.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36509060
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36181753
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36694078
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36401413
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2022 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36641
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
83000
CY2022 dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2022 dei City Area Code
CityAreaCode
201
CY2022 dei Local Phone Number
LocalPhoneNumber
488-0460
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
CY2022 dei Trading Symbol
TradingSymbol
BCLI
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
92955663
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36675251
CY2022 dei Auditor Name
AuditorName
Brightman Almagor Zohar & Co.
CY2022 dei Auditor Location
AuditorLocation
Tel Aviv, Israel
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
772000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18856000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
2211000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3238000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
91000
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
86000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1100000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3106000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
23280000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
23000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
27000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4389000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4781000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
933000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1189000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5345000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5997000
CY2022Q4 us-gaap Assets
Assets
8451000
CY2021Q4 us-gaap Assets
Assets
29277000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6224000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3700000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
84000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1427000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1461000
CY2022Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1065000
CY2021Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1073000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8800000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6317000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2666000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3618000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2666000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3618000
CY2022Q4 us-gaap Liabilities
Liabilities
11466000
CY2021Q4 us-gaap Liabilities
Liabilities
9935000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36694078
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36401413
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
194910000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192990000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197821000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173544000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8451000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29277000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13956000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15235000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10866000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9304000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-24822000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-24539000
CY2022 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-545000
CY2021 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-82000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24277000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24457000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36509060
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36181753
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1366000
CY2021 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
6964000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24457000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1682000
CY2022 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
238000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24277000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2022 us-gaap Profit Loss
ProfitLoss
-24277000
CY2021 us-gaap Profit Loss
ProfitLoss
-24457000
CY2022 us-gaap Depreciation
Depreciation
285000
CY2021 us-gaap Depreciation
Depreciation
260000
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1682000
CY2021 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1366000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-594000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-47000
CY2022 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1067000
CY2021 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-335000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2524000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1717000
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-7000
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2005000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19320000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26265000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
330000
CY2022 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1027000
CY2021 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-653000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
998000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
323000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2022 bcli Proceeds From At Market
ProceedsFromAtMarket
238000
CY2021 bcli Proceeds From At Market
ProceedsFromAtMarket
6964000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6969000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18084000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18973000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37829000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-198000000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;border:0;"><tr><td style="width:57.6pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Use of estimates:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 93.6pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect reported amounts and disclosures made. Actual results could differ from those estimates.</p>
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
933000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1189000
CY2022 us-gaap Depreciation
Depreciation
285000
CY2021 us-gaap Depreciation
Depreciation
260000
CY2022 bcli Short Term Deposits Policy Policytextblock
ShortTermDepositsPolicyPolicytextblock
<table style="border-collapse:collapse;border:0;"><tr><td style="width:57.6pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Short-term deposits:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 93.6pt;"><span style="font-weight:normal;">Short-term deposits are deposits with an original maturity of more than three months from the date of investment and which do not meet the definition of cash equivalents.</span></p>
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.0833
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.81
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0142
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0361
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0126
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24277000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24457000
CY2022 bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
CY2022 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4389000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4781000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4093000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5079000
CY2022 us-gaap Lease Cost
LeaseCost
2710000
CY2021 us-gaap Lease Cost
LeaseCost
2767000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2710000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0675
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1468000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1456000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1351000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
194000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4469000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
376000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4093000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3431000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3402000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2498000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2213000
CY2022 bcli Grants Underlying Basis
GrantsUnderlyingBasis
The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
CY2021 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P1Y
CY2022 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P1Y
CY2007Q3 bcli Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
672222
CY2017Q4 bcli Transaction Cost
TransactionCost
25000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250000
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
245000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
151000
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2802063
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.81
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
875000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1510117
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1310417
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y11M12D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M15D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1152850
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
995359
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
35000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
13.02
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1682000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1366000
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
14156000
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
15940000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13956000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15235000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
155310000
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
126800000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42683000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33641000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42683000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33641000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42683000
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
155310000
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
155310000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-9989000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8357000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-14288000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-16100000
CY2022 dei Auditor Firm
AuditorFirmId
1197

Files In Submission

Name View Source Status
0001410578-23-000426-index-headers.html Edgar Link pending
0001410578-23-000426-index.html Edgar Link pending
0001410578-23-000426.txt Edgar Link pending
0001410578-23-000426-xbrl.zip Edgar Link pending
bcli-20221231.xsd Edgar Link pending
bcli-20221231x10k.htm Edgar Link pending
bcli-20221231x10k001.jpg Edgar Link pending
bcli-20221231x10k003.jpg Edgar Link pending
bcli-20221231xex21.htm Edgar Link pending
bcli-20221231xex23d1.htm Edgar Link pending
bcli-20221231xex31d1.htm Edgar Link pending
bcli-20221231xex31d2.htm Edgar Link pending
bcli-20221231xex32d1.htm Edgar Link pending
bcli-20221231xex32d2.htm Edgar Link pending
bcli-20221231xex4d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
bcli-20221231_cal.xml Edgar Link unprocessable
bcli-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20221231x10k_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcli-20221231_def.xml Edgar Link unprocessable
bcli-20221231_lab.xml Edgar Link unprocessable